In 2020, the growth of China’s API export was stimulated by the epidemic, which boosted the global demand for ANTI-epidemic APIS, and also affected the production of other major API producers such as India and the European Union. As a result, the transfer orders of China’s API from the international market increased. Specifically, the export quantity of China’s API increased by 7.5% year on year, reaching 10.88 million tons. From specific export category, anti-infection, vitamins, hormones, antipyretic analgesic, part of antibiotic resistance to disease related API category of export amount is mostly realized the different levels of growth, some specific varieties is growing rapidly, such as dexamethasone exports rose 55% year-on-year, lamivudine, vitamin C, vitamin E and other exports more than 30% year-on-year growth, Paracetamol, annannin and other exports year-on-year growth of more than 20%.
The price of aminophylline is shaped by a complex interplay of factors, from production costs to insurance coverage. As the medical landscape continues to evolve, both healthcare providers and patients must stay informed about pricing trends and policies affecting this essential medication. Enhanced competition, regulatory reforms, and the introduction of generics can help improve accessibility, ensuring that individuals suffering from respiratory ailments can receive the treatment they need without financial hardship. Therefore, ongoing dialogue among stakeholders in the pharmaceutical industry, health policy, and patient advocacy remains vital in shaping the future landscape of aminophylline pricing and availability.